Clinical Report: ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response

Overview

The phase 2 ImmunoPRISM trial demonstrated that teclistamab significantly improves complete response rates and progression-free survival in patients with high-risk smoldering multiple myeloma compared to lenalidomide plus dexamethasone. Notably, 82% of patients treated with teclistamab achieved minimal residual disease negativity.

Background

High-risk smoldering multiple myeloma is a precursor to active multiple myeloma, with about 50% of patients progressing to active disease within two years. Current standard care involves observation, but recent studies suggest that early intervention may alter disease progression. The ImmunoPRISM trial is the first randomized study to evaluate a BCMA-targeted bispecific antibody in this patient population.

Data Highlights

Key Findings

• Teclistamab achieved a complete response in 75.6% of patients.
• 82% of patients treated with teclistamab became MRD-negative.
• Only 7% of teclistamab patients progressed after a median follow-up of 23.4 months.
• Estimated 2-year survival was 92% for teclistamab compared to 51% for the combination therapy.
• 71% of teclistamab patients experienced low-grade cytokine release syndrome.

Clinical Implications

The findings suggest that teclistamab may be a more effective treatment option for patients with high-risk smoldering multiple myeloma compared to the current standard of care. Early intervention with teclistamab could potentially alter the disease trajectory and improve patient outcomes.

Conclusion

The ImmunoPRISM trial provides compelling evidence for the efficacy of teclistamab in high-risk smoldering multiple myeloma, highlighting the potential benefits of early immunologic intervention.

Related Resources & Content

1. Dana-Farber Cancer Institute, ImmunoPRISM Trial, 2026 -- Teclistamab Improves Depth of Response
2. Blood Cancer Journal — Effects of Extramedullary and Paraskeletal Plasmacytomas on Treatment Outcomes in Multiple Myeloma Patients Receiving Teclistamab: Insights from the U.S. Myeloma Immunotherapy Consortium
3. The ASCO Post — Teclistamab in Previously Treated Multiple Myeloma
4. the asco post — High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
5. The ASCO Post — In Case You Missed It: Additional Studies of Interest From ASH 2024
6. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
7. Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma - The ASCO Post
8. ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma | Dana-Farber Cancer Institute
9. Teclistamab or Talquetamab in Combination with Daratumumab for the Treatment of High-Risk Smoldering Multiple Myeloma, The REVIVE Trial - NCI
10. FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma | FDA